Page last updated: 2024-09-04

birb 796 and transforming growth factor beta

birb 796 has been researched along with transforming growth factor beta in 2 studies

Compound Research Comparison

Studies (birb 796)	Trials (birb 796)	Recent Studies (post-2010) (birb 796)	Studies (transforming growth factor beta)	Trials (transforming growth factor beta)	Recent Studies (post-2010) (transforming growth factor beta)
137	5	80	49,119	560	17,610

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Anderson, KC; Hideshima, T; Ikeda, H; Ishitsuka, K; Jin, J; Kiziltepe, T; Moss, N; Ocio, EM; Okawa, Y; Pargellis, C; Podar, K; Raje, N; Richardson, PG; Vallet, S; Yasui, H	1
Chen, S; Du, L; Han, X; Hu, C; Jin, A; Li, L; Li, S; Pang, D; Shen, M; Tao, K; Wang, W; Zhang, J	1

Other Studies

2 other study(ies) available for birb 796 and transforming growth factor beta

Article	Year
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. British journal of haematology, 2007, Volume: 136, Issue:3 Topics: Antineoplastic Agents, Hormonal; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytotoxicity Tests, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Multiple Myeloma; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Signal Transduction; Stem Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2007
p38 inhibition enhances TCR-T cell function and antagonizes the immunosuppressive activity of TGF-β. International immunopharmacology, 2021, Volume: 98 Topics: Cell Line; Genetic Engineering; Granzymes; Humans; Immune Tolerance; Immunotherapy, Adoptive; Interferon-gamma; Lymphocyte Activation; MART-1 Antigen; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Receptors, Antigen, T-Cell; T-Lymphocytes; Transforming Growth Factor beta	2021

Article

Year

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

British journal of haematology, 2007, Volume: 136, Issue:3

Topics: Antineoplastic Agents, Hormonal; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytotoxicity Tests, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Multiple Myeloma; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Signal Transduction; Stem Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

2007

p38 inhibition enhances TCR-T cell function and antagonizes the immunosuppressive activity of TGF-β.

International immunopharmacology, 2021, Volume: 98

Topics: Cell Line; Genetic Engineering; Granzymes; Humans; Immune Tolerance; Immunotherapy, Adoptive; Interferon-gamma; Lymphocyte Activation; MART-1 Antigen; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Receptors, Antigen, T-Cell; T-Lymphocytes; Transforming Growth Factor beta

2021